SCHEMBL17599334

SCHEMBL17599334

Cc1c(S(=O)(=O)Nc2ccc(-c3cc(C(=O)O)ccc3F)c3ncccc23)sc2cccc(F)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PFKFB4 Q16877 5/20 0.41
▸ PFKFB3 Q16875 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ CMA1 P23946 3/20 0.39
▸ GLO1 Q04760 1/20 0.39
▸ SLC40A1 Q9NP59 2/20 0.38
▸ CKS1B P61024 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MMP2 P08253 2/20 0.36
▸ MMP9 P14780 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PKLR P30613 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599377 0.86 PFKFB3 (0.56) PFKFB4PFKFB3CMA1
SCHEMBL17599375 0.75 ACLY (0.49) KDM4EGLO1SLC40A1CKS1BSKP2
SCHEMBL17599357 0.75 KDM4E (0.46) KDM4EGLO1SLC40A1MMP2MMP9
SCHEMBL17613337 0.75 PFKFB3 (0.63) PFKFB4PFKFB3CMA1
SCHEMBL17599461 0.74 KEAP1 (0.65) KDM4ESLC40A1TDP1MMP2MMP9
SCHEMBL17599341 0.72 FABP4 (0.43) PFKFB4PFKFB3CMA1KMT2AALDH1A1
SCHEMBL17599395 0.71 KDM4E (0.37) KDM4EGLO1SLC40A1TDP1MEN1
SCHEMBL17599370 0.69 ALDH1A1 (0.53) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL17599349 0.68 MEN1 (0.43) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL17599385 0.67 TSHR (0.47) KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback